NanoViricides Announces 2025 Annual Shareholders Meeting Amid Clinical Development Progress

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to prevent viral escape, has announced that its Annual Shareholders Meeting will be held at 10 a.m. on Saturday, November 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. The company, which focuses on creating special purpose nanomaterials for antiviral therapy, is currently advancing multiple drug candidates through its development pipeline.

The company's lead drug candidate is NV-387, a broad-spectrum antiviral drug planned for development as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Another advanced candidate is NV-HHV-1 for the treatment of Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, though the company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.

NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology licensed from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license to this technology for several drugs targeting specific viral diseases, including Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, and Ebola/Marburg viruses, among others. The company intends to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful.

The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. According to the company's memorandum of understanding with TheraCour, the development partnership covers drugs for all antiviral infections but excludes cancer and similar diseases that may have viral origin but require different kinds of treatments. Additional information about the company's development programs and technology platform is available at https://www.nanoviricides.com.

As with any pharmaceutical development company, NanoViricides acknowledges that the path to typical drug development is extremely lengthy and requires substantial capital. The company states there can be no assurance that any of its pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development, nor that successful laboratory results against coronavirus will lead to successful clinical trials or a marketable pharmaceutical product. The upcoming shareholders meeting provides investors with an opportunity to receive updates on the company's progress across its diverse antiviral development portfolio.